Paper Details

  1. Home
  2. Paper Details

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.

Author: BartonSamantha, EdwardsSteven J, ThurgarElizabeth, TrevorNicola

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ovarian cancer is a common and serious cancer in the UK. While initial chemotherapy is effective, the cancer returns in 55-75% of people within two years. The best chemotherapy regimen for treating recurrent, advanced ovarian cancer is still uncertain.
Paper Details　
Original Abstract of the Article :
Ovarian cancer is the fifth most common cancer in the UK, and the fourth most common cause of cancer death. Of those people successfully treated with first-line chemotherapy, 55-75% will relapse within 2 years. At this time, it is uncertain which chemotherapy regimen is more clinically effective and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781035/

データ提供：米国国立医学図書館（NLM）

The Search for Effective Treatments for Recurrent Ovarian Cancer

The desert of [recurrent ovarian cancer] can be a daunting place, with limited treatment options and high rates of relapse. This study delves into the [clinical effectiveness] and [cost-effectiveness] of several chemotherapy regimens for [advanced recurrent ovarian cancer]. The researchers conducted a [systematic review] to assess the available evidence and to provide guidance for healthcare providers making treatment decisions.

Navigating the Desert: A Comprehensive Analysis of Chemotherapy Regimens

Imagine a caravan encountering a series of treacherous sandstorms. Each storm represents a different [chemotherapy regimen], and the caravan must choose the safest and most effective path. This study systematically evaluates the [clinical effectiveness] and [cost-effectiveness] of several chemotherapy regimens, providing valuable insights into the options available for patients with [recurrent ovarian cancer].

A Guide to Treatment: Implications for Ovarian Cancer Care

This study provides a much-needed guide for [healthcare providers] making treatment decisions for [patients with recurrent ovarian cancer]. The researchers have conducted a comprehensive analysis of the available evidence, highlighting the [strengths and weaknesses] of different chemotherapy regimens. By considering both [clinical effectiveness] and [cost-effectiveness], they provide a more holistic perspective on treatment options.

Dr.Camel's Conclusion

This research serves as a valuable compass in the challenging landscape of [recurrent ovarian cancer]. By providing a thorough analysis of the available [chemotherapy regimens], the researchers have equipped healthcare providers with the knowledge they need to make informed treatment decisions. Just as a wise camel navigates the desert, healthcare providers must carefully consider the [individual needs] of their patients and the [potential benefits and risks] of different treatment options.

Date :
  1. Date Completed 2015-10-21
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25626481

DOI: Digital Object Identifier

PMC4781035

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.